Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Pauline, Veyrard"'
Autor:
Pauline Veyrard, Xavier Roblin, Céline Pansart, Ren Mao, Stéphane Nancey, Martin Killian, Louis Waeckel, Anne-Emmanuelle Berger, Nicolas Williet, Laetitia Bastide, Mathilde Barrau, Quentin Tournier, Stéphane Paul
Publikováno v:
Clinical Immunology Communications, Vol 2, Iss , Pp 33-38 (2022)
Aim: Serum calprotectin (SC), a novel biomarker of inflammatory bowel diseases (IBD), has been recently investigated with conflicting results. The purpose of this study was to assess the ability of SC to predict relapse in IBD patients treated by bio
Externí odkaz:
https://doaj.org/article/2caf60cdd62543b4a4c3263434463a11
Autor:
Mathilde Barrau, Manon Duprat, Pauline Veyrard, Quentin Tournier, Nicolas Williet, Jean Marc Phelip, Louis Waeckel, Adam S Cheifetz, Konstantinos Papamichael, Xavier Roblin, Stephane Paul
Publikováno v:
Journal of Crohn's and Colitis. 17:633-643
Many patients with inflammatory bowel disease [IBD] are treated with anti-tumour necrosis factor [TNF] therapies, of which infliximab [IFX] is most commonly used. Loss of response [LOR] to anti-TNF therapy due to immunogenic failure accounts for 20%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f5152920f7fb6bf34bf23b0da08e8b
https://doi.org/10.1093/ecco-jcc/jjac164
https://doi.org/10.1093/ecco-jcc/jjac164
Autor:
Pauline Veyrard, Gauthier Pellet, David Laharie, Maria Nachury, Pascal Juillerat, Xavier Roblin
Publikováno v:
Veyrard, P; Pellet, G; Laharie, D; Nachury, M; Juillerat, P; Roblin, X (2023). Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis. Clinical gastroenterology and hepatology, 21(5), 1354-1355.e2. Elsevier 10.1016/j.cgh.2022.03.008
Ulcerative colitis is a chronic inflammatory bowel disease. Approximately 20% of patients experience an acute severe attack during their life. In acute severe ulcerative colitis (ASUC), first-line therapy is intravenous (IV) steroids. In the absence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7851a4a3743fcd64dd18b05d2a21d31
https://boris.unibe.ch/167856/1/1-s2.0-S1542356522002828-main.pdf
https://boris.unibe.ch/167856/1/1-s2.0-S1542356522002828-main.pdf
Autor:
Alexandre Jentzer, Pauline Veyrard, Xavier Roblin, Pierre Saint-Sardos, Nicolas Rochereau, Stéphane Paul, Thomas Bourlet, Bruno Pozzetto, Sylvie Pillet
Publikováno v:
Microorganisms, Vol 8, Iss 7, p 1078 (2020)
Cytomegalovirus (CMV) infects approximately 40% of adults in France and persists lifelong as a latent agent in different organs, including gut. A close relationship is observed between inflammation that favors viral expression and viral replication t
Externí odkaz:
https://doaj.org/article/5b026fba27b549d2bd4dcc9b95b6ad5e
Autor:
Jean-Marc Phelip, Bernard Flourié, Pauline Veyrard, Gilles Boschetti, Martin Killian, Anne-Emmanuelle Berger, Xavier Roblin, Stéphane Paul, Nicolas Williet, Capucine Genin, Louis Waeckel, Stéphane Nancey
Publikováno v:
Inflammatory Bowel Diseases. 28:720-727
Background In cases of loss of response due to mechanistic failure under antitumor necrosis factor agents, it is recommended to switch to another class of biologics. Two different strategies were compared in patients with inflammatory bowel disease (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd0e60b1d03e76274b9dfefabcf7eba
https://doi.org/10.1093/ibd/izab158
https://doi.org/10.1093/ibd/izab158
Autor:
Stéphane Nancey, Pauline Veyrard, Gilles Boschetti, Jean-Marc Phelip, Bernard Flourié, Stéphane Paul, Xavier Roblin, Nicolas Williet
Publikováno v:
Digestive Diseases and Sciences. 66:2744-2749
The pharmacokinetic equivalence of dose intensification with adalimumab (ADA) 80 mg every other week (EOW) compared to weekly 40 mg has only been supported by modeling systems. To compare the trough levels of ADA (TLA) and the occurrence of anti-ADA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5fbf25e15e80508063ec502f3f740b9
https://doi.org/10.1007/s10620-020-06567-x
https://doi.org/10.1007/s10620-020-06567-x
Autor:
Lieven Pouillon, Guillaume Bouguen, Bernard Flourié, Mathurin Fumery, Stephanie Viennot, Laurent Siproudhis, Franck Brazier, Jérôme Filippi, Pauline Veyrard, Florian Poullenot, Anthony Buisson, Lucile Boivineau, Xavier Treton, Momar Diouf, David Laharie, Cyrielle Gilletta, Stéphane Nancey, Romain Altwegg, Xavier Roblin, Anne Bozon, Laurent Peyrin-Biroulet
Publikováno v:
Journal of Crohn's and Colitis. 15:222-227
Background The approved maintenance regimens for ustekinumab in Crohn’s disease [CD] are 90 mg every 8 or 12 weeks. Some patients will respond partially to ustekinumab or will experience a secondary loss of response. It remains poorly known if thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f90a6410b127e25aeaf6e4ba6f389e2
https://doi.org/10.1093/ecco-jcc/jjaa177
https://doi.org/10.1093/ecco-jcc/jjaa177
Autor:
Xavier Roblin, Pauline Veyrard, Laetitia Bastide, Anne E. Berger, Mathilde Barrau, Anne‐Sophie Paucelle, Louis Waeckel, Sany Kwiatek, Bernard Flourie, Stephane Nancey, Stéphane Paul
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 56(1)
The new subcutaneous (sc) formulation of the infliximab (IFX) biosimilar CT-P13 results in homogeneous serum trough concentrations of IFX at steady state. The present study aimed to investigate in Crohn's disease (CD) patients the intra-individual va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1559633ab32a002b9e2376d105433b
https://pubmed.ncbi.nlm.nih.gov/35229331
https://pubmed.ncbi.nlm.nih.gov/35229331
Autor:
Shomron Ben-Horin, Ofir Har-Noy, Konstantinos H. Katsanos, Xavier Roblin, Minhu Chen, Xiang Gao, Doron Schwartz, Jae Hee Cheon, Monica Cesarini, Daniela Bojic, Marijana Protic, Angeliki Theodoropoulou, Heba Abu-Kaf, Tal Engel, Jian Tang, Pauline Veyrard, Xiaoqing Lin, Ren Mao, Dimitrios Christodoulou, Konstantinos Karmiris, Tamara Knezevic-Ivanovski
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:2868-2875.e1
Corticosteroids are the mainstay of treatment for hospitalized patients with acute severe ulcerative colitis (ASUC). However, whether the addition/continuation of mesalamine with corticosteroids during hospitalization is superior to corticosteroids a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eb29574af6d5f45c1184ed2c134b955
https://doi.org/10.1016/j.cgh.2022.02.055
https://doi.org/10.1016/j.cgh.2022.02.055
Autor:
Bella Ungar, Rami Eliakim, Xavier Roblin, Pauline Veyrard, Uri Kopylov, Emilie Del Tedesco, Gal Ben-Haim, Zohar Ben-Shatach, Shomron Ben-Horin, Orit Picard, Miri Yavzori, Stéphane Paul, Ella Fudim
Publikováno v:
Digestive and Liver Disease. 51:1106-1111
Loss of response (LOR) to infliximab occurs in ∼30% of IBD patients. At time of LOR, lower infliximab-trough-levels (TL), in the absence of anti-drug-antibodies (ATI), have been associated with the need for therapy escalation. Nevertheless, few stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c002791905437429ccbcb79cfcd0b2a
https://doi.org/10.1016/j.dld.2019.02.013
https://doi.org/10.1016/j.dld.2019.02.013